Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
QualityStar will present at the Cambridge Healthtech Institute’s Ninth Annual Biomarkers and Diagnostics World Congress a new application that uses whole-slide digital imaging (WSI) for anatomic pathology external peer review quality assurance. The presentation will review current quality assurance programs and the application of WSI as an approach to gain longitudinal benchmarking data for quality review.
Quidel has received FDA 510(k) clearance for its Molecular RSV and hMPV assay for the detection of respiratory syncytial virus and human metapneumovirus. The assay distinguishes between RSV and hMPV. The RSV and hMPV assay can be batched alongside other Quidel Molecular assays, such as the influenza A and B PCR assay, in the same multiwell panel for customized multiplexing capability.
Agilent Technologies’ HaloPlex exome kits and SureCall software complement the company’s Web-based SureDesign interface and custom HaloPlex gene panels to provide a complete, integrated workflow. The HaloPlex exome kit comprises about 2.5 million probes to provide comprehensive coverage of the coding regions of the human genome with minimal hands-on time. The kit requires only 200 ng of input DNA.
Advanced Cell Diagnostics has entered into an agreement with Johns Hopkins University on behalf of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, whereby ACD’s RNAscope technology will be used to validate novel biomarkers and drug targets for cancer immunotherapy.
Dako’s Omnis solution, a new addition to the company’s immunohistochemistry portfolio, consists of hardware, software, and reagents. It automates IHC and ISH processes, allowing entire patient cases to be processed simultaneously. The solution offers continuous loading, batch loading, and overnight run options. Its state-of-the-art software allows slide processing and instrument maintenance to be traced to individual operators, greatly increasing quality control.
Epigenomics has submitted to the FDA the fourth and final module of its premarket approval for its blood-based Epi proColon test for the detection of colorectal cancer.
PerkinElmer’s Ivis Lumina series III benchtop platform is for oncology, infectious disease, and drug discovery and efficacy research. The system integrates bioluminescence and full spectral fluorescence in vivo imaging technologies, providing an expandable and sensitive benchtop imaging platform.
Sarstedt’s Minivette POCT is a device for the precise and hygienic collection, transfer, and subsequent dispensing of small capillary blood samples for point-of-care tests.
Thermo Fisher Scientific’s Syncronis high-performance liquid chromatography columns are now available with 3-mm particle size. The new size complements the existing 1.7- and 5-µm particle sizes.
Horizon Discovery was named the most promising company at the Personalized Medicine World Conference 2013. Horizon was chosen from 32 shortlisted companies based on technology, historical performance of the company, and forward business plans.
